MTD acquires Ypsomed's pen needle and BGM businesses, strengthening its leading position in diabetes care

Charles Bouaziz, CEO of MTD, expresses enthusiasm for the partnership with Ypsomed and the opportunities it brings. "This acquisition will enable us to accelerate growth and enter new strategic markets, leveraging a broader product portfolio combining the 6-bevels and click technologies from Ypsomed and MTD's thinnest and shortest 34G pen needle. We will integrate Ypsomed's pen needles operations and BGMs' commercialization into our European production and distribution sites, contributing to scale efficiencies and benefiting from our category expertise, says Charles Bouaziz, CEO of MTD.

MILAN, 27/03/2024 (informazione.it - comunicati stampa - salute e benessere)

Charles Bouaziz , CEO of MTD, expresses enthusiasm for the partnership with Ypsomed and the opportunities it brings. says Charles Bouaziz , CEO of MTD.

"  – continues Bouaziz - ."

The closing of the transaction and thus the transfer of the business with pen needles and blood glucose monitoring systems is expected in summer 2024, after which the transition will begin, and is subject to customary conditions.

 

View original content: https://www.prnewswire.co.uk/news-releases/mtd-acquires-ypsomeds-pen-needle-and-bgm-businesses-strengthening-its-leading-position-in-diabetes-care-302100986.html